Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles

Kenji Tamura, Mutsuo Furihata, Tatsuhiko Tsunoda, Shingo Ashida, Ryo Takata, Wataru Obara, Hiroki Yoshioka, Yataro Daigo, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Konaka, Mikio Namiki, Keiichi Tozawa, Kenjiro Kohri, Nozomu Tanji, Masayoshi Yokoyama, Toru Shimazui, Hideyuki Akaza, Yoichi Mizutani, Tsuneharu MikiTomoaki Fujioka, Taro Shuin, Yusuke Nakamura, Hidewaki Nakagawa

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

One of the most critical issues in prostate cancer clinic is emerging hormone-refractory prostate cancers (HRPCs) and their management. Prostate cancer is usually androgen dependent and responds well to androgen ablation therapy. However, at a certain stage, they eventually acquire androgen-independent and more aggressive phenotype and show poor response to any anticancer therapies. To characterize the molecular features of clinical HRPCs, we analyzed gene expression profiles of 25 clinical HRPCs and 10 hormone-sensitive prostate cancers (HSPCs) by genome-wide cDNA microarrays combining with laser microbeam microdissection. An unsupervised hierarchical clustering analysis clearly distinguished expression patterns of HRPC cells from those of HSPC cells. In addition, primary and metastatic HRPCs from three patients were closely clustered regardless of metastatic organs. A supervised analysis and permutation test identified 36 up-regulated genes and 70 down-regulated genes in HRPCs compared with HSPCs (average fold difference > 1.5; P <0.0001). We observed overexpression of AR, ANLN, and SNRPE and down-regulation of NR4A1, CYP27A1, and HLA-A antigen in HRPC progression. AR overexpression is likely to play a central role of hormone-refractory phenotype, and other genes we identified were considered to be related to more aggressive phenotype of clinical HRPCs, and in fact, knockdown of these overexpressing genes by small interfering RNA resulted in drastic attenuation of prostate cancer cell viability. Our microarray analysis of HRPC cells should provide useful information to understand the molecular mechanism of HRPC progression and to identify molecular targets for development of HRPC treatment.

Original languageEnglish
Pages (from-to)5117-5125
Number of pages9
JournalCancer Research
Volume67
Issue number11
DOIs
Publication statusPublished - Jun 1 2007

Fingerprint

Transcriptome
Prostatic Neoplasms
Genome
Hormones
Androgens
Phenotype
Genes
Gene Knockdown Techniques
Microdissection
HLA-A Antigens
Neoplasm Genes
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Small Interfering RNA
Cluster Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tamura, K., Furihata, M., Tsunoda, T., Ashida, S., Takata, R., Obara, W., ... Nakagawa, H. (2007). Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Research, 67(11), 5117-5125. https://doi.org/10.1158/0008-5472.CAN-06-4040

Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. / Tamura, Kenji; Furihata, Mutsuo; Tsunoda, Tatsuhiko; Ashida, Shingo; Takata, Ryo; Obara, Wataru; Yoshioka, Hiroki; Daigo, Yataro; Nasu, Yasutomo; Kumon, Hiromi; Konaka, Hiroyuki; Namiki, Mikio; Tozawa, Keiichi; Kohri, Kenjiro; Tanji, Nozomu; Yokoyama, Masayoshi; Shimazui, Toru; Akaza, Hideyuki; Mizutani, Yoichi; Miki, Tsuneharu; Fujioka, Tomoaki; Shuin, Taro; Nakamura, Yusuke; Nakagawa, Hidewaki.

In: Cancer Research, Vol. 67, No. 11, 01.06.2007, p. 5117-5125.

Research output: Contribution to journalArticle

Tamura, K, Furihata, M, Tsunoda, T, Ashida, S, Takata, R, Obara, W, Yoshioka, H, Daigo, Y, Nasu, Y, Kumon, H, Konaka, H, Namiki, M, Tozawa, K, Kohri, K, Tanji, N, Yokoyama, M, Shimazui, T, Akaza, H, Mizutani, Y, Miki, T, Fujioka, T, Shuin, T, Nakamura, Y & Nakagawa, H 2007, 'Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles', Cancer Research, vol. 67, no. 11, pp. 5117-5125. https://doi.org/10.1158/0008-5472.CAN-06-4040
Tamura, Kenji ; Furihata, Mutsuo ; Tsunoda, Tatsuhiko ; Ashida, Shingo ; Takata, Ryo ; Obara, Wataru ; Yoshioka, Hiroki ; Daigo, Yataro ; Nasu, Yasutomo ; Kumon, Hiromi ; Konaka, Hiroyuki ; Namiki, Mikio ; Tozawa, Keiichi ; Kohri, Kenjiro ; Tanji, Nozomu ; Yokoyama, Masayoshi ; Shimazui, Toru ; Akaza, Hideyuki ; Mizutani, Yoichi ; Miki, Tsuneharu ; Fujioka, Tomoaki ; Shuin, Taro ; Nakamura, Yusuke ; Nakagawa, Hidewaki. / Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. In: Cancer Research. 2007 ; Vol. 67, No. 11. pp. 5117-5125.
@article{3888f58e3d144106b48a0fe394a47e0a,
title = "Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles",
abstract = "One of the most critical issues in prostate cancer clinic is emerging hormone-refractory prostate cancers (HRPCs) and their management. Prostate cancer is usually androgen dependent and responds well to androgen ablation therapy. However, at a certain stage, they eventually acquire androgen-independent and more aggressive phenotype and show poor response to any anticancer therapies. To characterize the molecular features of clinical HRPCs, we analyzed gene expression profiles of 25 clinical HRPCs and 10 hormone-sensitive prostate cancers (HSPCs) by genome-wide cDNA microarrays combining with laser microbeam microdissection. An unsupervised hierarchical clustering analysis clearly distinguished expression patterns of HRPC cells from those of HSPC cells. In addition, primary and metastatic HRPCs from three patients were closely clustered regardless of metastatic organs. A supervised analysis and permutation test identified 36 up-regulated genes and 70 down-regulated genes in HRPCs compared with HSPCs (average fold difference > 1.5; P <0.0001). We observed overexpression of AR, ANLN, and SNRPE and down-regulation of NR4A1, CYP27A1, and HLA-A antigen in HRPC progression. AR overexpression is likely to play a central role of hormone-refractory phenotype, and other genes we identified were considered to be related to more aggressive phenotype of clinical HRPCs, and in fact, knockdown of these overexpressing genes by small interfering RNA resulted in drastic attenuation of prostate cancer cell viability. Our microarray analysis of HRPC cells should provide useful information to understand the molecular mechanism of HRPC progression and to identify molecular targets for development of HRPC treatment.",
author = "Kenji Tamura and Mutsuo Furihata and Tatsuhiko Tsunoda and Shingo Ashida and Ryo Takata and Wataru Obara and Hiroki Yoshioka and Yataro Daigo and Yasutomo Nasu and Hiromi Kumon and Hiroyuki Konaka and Mikio Namiki and Keiichi Tozawa and Kenjiro Kohri and Nozomu Tanji and Masayoshi Yokoyama and Toru Shimazui and Hideyuki Akaza and Yoichi Mizutani and Tsuneharu Miki and Tomoaki Fujioka and Taro Shuin and Yusuke Nakamura and Hidewaki Nakagawa",
year = "2007",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-06-4040",
language = "English",
volume = "67",
pages = "5117--5125",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles

AU - Tamura, Kenji

AU - Furihata, Mutsuo

AU - Tsunoda, Tatsuhiko

AU - Ashida, Shingo

AU - Takata, Ryo

AU - Obara, Wataru

AU - Yoshioka, Hiroki

AU - Daigo, Yataro

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Konaka, Hiroyuki

AU - Namiki, Mikio

AU - Tozawa, Keiichi

AU - Kohri, Kenjiro

AU - Tanji, Nozomu

AU - Yokoyama, Masayoshi

AU - Shimazui, Toru

AU - Akaza, Hideyuki

AU - Mizutani, Yoichi

AU - Miki, Tsuneharu

AU - Fujioka, Tomoaki

AU - Shuin, Taro

AU - Nakamura, Yusuke

AU - Nakagawa, Hidewaki

PY - 2007/6/1

Y1 - 2007/6/1

N2 - One of the most critical issues in prostate cancer clinic is emerging hormone-refractory prostate cancers (HRPCs) and their management. Prostate cancer is usually androgen dependent and responds well to androgen ablation therapy. However, at a certain stage, they eventually acquire androgen-independent and more aggressive phenotype and show poor response to any anticancer therapies. To characterize the molecular features of clinical HRPCs, we analyzed gene expression profiles of 25 clinical HRPCs and 10 hormone-sensitive prostate cancers (HSPCs) by genome-wide cDNA microarrays combining with laser microbeam microdissection. An unsupervised hierarchical clustering analysis clearly distinguished expression patterns of HRPC cells from those of HSPC cells. In addition, primary and metastatic HRPCs from three patients were closely clustered regardless of metastatic organs. A supervised analysis and permutation test identified 36 up-regulated genes and 70 down-regulated genes in HRPCs compared with HSPCs (average fold difference > 1.5; P <0.0001). We observed overexpression of AR, ANLN, and SNRPE and down-regulation of NR4A1, CYP27A1, and HLA-A antigen in HRPC progression. AR overexpression is likely to play a central role of hormone-refractory phenotype, and other genes we identified were considered to be related to more aggressive phenotype of clinical HRPCs, and in fact, knockdown of these overexpressing genes by small interfering RNA resulted in drastic attenuation of prostate cancer cell viability. Our microarray analysis of HRPC cells should provide useful information to understand the molecular mechanism of HRPC progression and to identify molecular targets for development of HRPC treatment.

AB - One of the most critical issues in prostate cancer clinic is emerging hormone-refractory prostate cancers (HRPCs) and their management. Prostate cancer is usually androgen dependent and responds well to androgen ablation therapy. However, at a certain stage, they eventually acquire androgen-independent and more aggressive phenotype and show poor response to any anticancer therapies. To characterize the molecular features of clinical HRPCs, we analyzed gene expression profiles of 25 clinical HRPCs and 10 hormone-sensitive prostate cancers (HSPCs) by genome-wide cDNA microarrays combining with laser microbeam microdissection. An unsupervised hierarchical clustering analysis clearly distinguished expression patterns of HRPC cells from those of HSPC cells. In addition, primary and metastatic HRPCs from three patients were closely clustered regardless of metastatic organs. A supervised analysis and permutation test identified 36 up-regulated genes and 70 down-regulated genes in HRPCs compared with HSPCs (average fold difference > 1.5; P <0.0001). We observed overexpression of AR, ANLN, and SNRPE and down-regulation of NR4A1, CYP27A1, and HLA-A antigen in HRPC progression. AR overexpression is likely to play a central role of hormone-refractory phenotype, and other genes we identified were considered to be related to more aggressive phenotype of clinical HRPCs, and in fact, knockdown of these overexpressing genes by small interfering RNA resulted in drastic attenuation of prostate cancer cell viability. Our microarray analysis of HRPC cells should provide useful information to understand the molecular mechanism of HRPC progression and to identify molecular targets for development of HRPC treatment.

UR - http://www.scopus.com/inward/record.url?scp=34347241757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347241757&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-4040

DO - 10.1158/0008-5472.CAN-06-4040

M3 - Article

C2 - 17545589

AN - SCOPUS:34347241757

VL - 67

SP - 5117

EP - 5125

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 11

ER -